Induction of thymidine phosphorylase expression and enhancement of furtulon sensitivity by taxol in a human ovarian carcinoma cell line

Anticancer Research

Volumn 23, Issue 3 B, 2003, Pages 2665-2669

  Hata, Kohkichi ^a   Osaki, Mitsuhiko ^b   Kanasaki, Haruhiko ^a   Nakayama, Kentaro ^a   Fujiwaki, Ritsuto ^a   Ito, Hisao ^b   Miyazaki, Kohji ^a  

^a SHIMANE UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

Author keywords

Drug sensitivity; Furtulon; Human ovarian carcinoma cell line; Taxol; Thymidine phosphorylase

Indexed keywords

5' DEOXY DEXTRO RIBOSE 1 PHOSPHATE; DEOXYRIBOSE; DOXIFLURIDINE; FLUOROURACIL; PACLITAXEL; THYMIDINE; THYMIDINE PHOSPHORYLASE; THYMINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG METABOLISM; DRUG SENSITIVITY; HUMAN; HUMAN CELL; NUCLEOTIDE METABOLISM; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIVISION; DRUG SYNERGISM; ENZYME INDUCTION; FEMALE; FLOXURIDINE; GENE EXPRESSION; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PRODRUGS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYMIDINE PHOSPHORYLASE; TUMOR CELLS, CULTURED;

EID: 0042306396     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Yoshimura A, Kuwazuru Y, Furukawa T, Yoshida H, Yamada K and Akiyama S: Purification and tissue distribution of human thymidine phosphorylase: high expression in lymphocytes, reticulocytes and tumors. Biochim Biophys Acta 1034: 107-113, 1999.
2. Pauly JL, Schuller MG, Zelcer AA, Kriss TA, Gore SS and Germain MJ: Identification and comparative analysis of thymidine phosphorylase in the plasma of healthy subjects and cancer patients. J Natl Cancer Inst 58: 1587-1590, 1997.
3. Hata K, Kamikawa T, Arao S, Tashiro H, Katabuchi H, Okamura H, Fujiwaki R, Miyazaki K and Fukumoto F: Expression of the thymidine phosphorylase gene in epithelial ovarian cancer. Br J Cancer 79: 1848-1854, 1999.
4. Hata K, Fujiwaki R, Maede Y, Nakayama K, Fukumoto F and Miyazaki K: Expression of thymidine phosphorylase in epithelial ovarian cancer: correlation with angiogenesis, apoptosis, and ultrasound-derived peak systolic velocity. Gynecol Oncol 77: 26-34, 2000.
5. Kono A, Hara Y, Sugata S, Karube Y, Matsushima Y and Ishitsuka H: Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharma Bull 31: 175-178, 1983.
6. Berne M, Gustavsson B, Almersjo O, Spears P and Sundstrom E: Inhibition of thymidylate synthase after administration of doxifluridine in a transplantable colon carcinoma in the rat. Cancer Invest 6: 377-383, 1988.
7. Patterson AV, Zhang H, Moghaddam A, Bicknell R, Talbot DC, Stratford IJ and Harris AL: Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer 72: 669-675, 1995.
8. Kato Y, Matsukawa S, Muraoka R and Tanigawa N: Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA. Br J Cancer 75: 506-511, 1997.
9. Chu E, Lai G, Zinn S and Allegra CJ: Resitance of a human ovarian cancer line to 5-fluorouracil associated with decreased levels of 5-fluorouracil in DNA. Mol Pharmacol 38: 410-417, 1990.
10. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T and Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of Capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 4: 1013-1019, 1998.
11. Yamamoto K, Kikuci Y, Kudoh K and Nagata I: Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. J Cancer Res Clin Oncol 126: 168-172, 2000.
12. Hata K, Fujiwaki R, Nakayama K, Fukumoto M and Miyazaki K: Expression of TP and TIE2 genes in normal ovary with corpus luteum and in ovarian cancer; correlation with ultrasound-derived peak systolic velocity. Mol Hum Reprod 6: 319-323, 2000.
13. Neijt JP: Optimum chemotherapy regimen, dose intensity, and new drugs. In: Epithelial Cancer of the Ovary (Lawton FG, Neijt JP and Swenerton KD, eds). London, BMJ Publishing Group, 1995: pp 186-208.
14. Burkhart CA, Berman JW, Swindell CS and Horwitz SB: Relationship between the structure of Taxol and other Taxanes on induction of tumor necrosis factor-alpha gene expression and cytotoxicity. Cancer Res 54: 5779-5782, 1994.
15. Eda H, Fujimoto K, Watanabe S, Ura M, Hino A, Tanaka Y, Wada K and Ishitsuka H: Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 32: 333-338, 1993.
16. Cheng L, Zheng S, Raghunathan K, Priest DG, Willingham MC, Norris JS and Fan M: Characterization of Taxol-induced apoptosis and altered gene expression in human breast cancer cells. Cell Pharmacol 2: 249-257, 1995.
17. Johnson KR, Wang L, Miller MC III, Willingham MC and Fan W: 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells. Clin Cancer Res 3: 1739-1745, 1997.
18. Johnson KR, Young KK and Fan W: Antagonistic interplay between antimitotic and G1-S arresting agents observed in experimental combination therapy. Clin Cancer Res 5: 2559-2565, 1999.
19. Huang Y, Johnson KR, Norris JS and Weimin F: Nuclear factor-kB/IkB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 60: 4426-4432, 2000.
20. Wohlhueter RM, Marz R and Plagemann PG: Thymidine transport in cultured mammalian cells: kinetic analysis, temperature dependence and specificity of the transport system. Biochim Biophys Acta 553: 262-283, 1979.
21. O'Dwyer PJ, King SA, Hoth DF and Leyland-Jones B: Role of thymidine in biochemical modulation: a review. Cancer Res 47: 3911-3919, 1987.
22. Stevenson DP, Milligan SR and Collins WP: Effect of platelet-derived endothelial cell growth factor/thymidine phosphorylase, substrate, and products in a three-dimensional model of angiogenesis. Am J Pathol 153: 1641-1646, 1998.
23. Kitazono M, Takebayashi Y, Ishitsuka K, Takao S, Tani A, Furukawa T, Miyadera K, Yamada Y, Aikou T and Akiyama S: Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase. Biochem Biophy Res Commun 253: 797-803, 1998.
24. Stevenson DP, Collins WP, Farzaneh F, Hata K and Miyazaki K: Thymidine phosphorylase activity and prodrug effects in a three-dimensional model of angiogenesis: implications for the treatment of ovarian cancer. Am J Pathol 153: 1573-1578, 1998.
25. Tanaka Y, Eda H, Fujimoto K, Tanaka T, Ishikawa T and Ishistuka H: Anticachectic activity of 5'-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma. Cancer Res 50: 4528-4532, 1990.
26. Eda H, Tanaka Y and Ishistuka H: 5'-deoxy-5-fluorouridine improves cachexia by a mechanism independent of its antiproliferative action in colon 26 adenocarcinoma-bearing mice. Cancer Chemother Pharmacol 29: 1-6, 1991.
27. Bertram JS: Fifth Heidelberger conference on targets for cancer research: prevention, differentiation, and selective therapy. Cancer Res 55: 705-709, 1995.
28. Senderoff RI, Weber PA, Smith DR and Sokoloski TD: Evaluation of antiproliferative agents using a cell-culture model. Invest Ophthalmol Vis Sci 31: 2572-2578, 1990.
29. Choong YS, Lee SP and Alley PA: Comparison of the pyrimidine nucleoside phosphorylase activity in human tumors and normal tissues. Exp Pathol 33: 23-25, 1998.
30. Armstrong RD and Diasio RB: Selective activation of 5'-deoxy-5-fluorouridine by tumor cells as a basis for an improved therapeutic index. Cancer Res 41: 4891-4894, 1991.
31. Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B and Reigner B: Phase I and pharmacologic study of intermittent twice-daily oral therapy with Capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16: 2977-2985, 1998.